Burundi vs Guinea-Bissau: Average cost of multi drug-resistant tuberculosis treatment
Burundi
1,051 constant 2022 US$
in 2024
Guinea-Bissau
1,120 constant 2022 US$
in 2024
Burundi rank
45th
Guinea-Bissau rank
43rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Burundi
- Guinea-Bissau
How they compare
Guinea-Bissau currently reports 1,120 constant 2022 US$ against 1,051 constant 2022 US$ in Burundi, a difference of 69 constant 2022 US$.
That makes Guinea-Bissau's figure about 1.1 times Burundi's.
The two have swapped places 6 times across 8 shared years of data; in 2017 it was Guinea-Bissau ahead.
Burundi ranks 45th and Guinea-Bissau ranks 43rd of 92 countries.
Guinea-Bissau has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burundi | Guinea-Bissau | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,711 constant 2022 US$ | 2,481 constant 2022 US$ | 770.33 constant 2022 US$ | Guinea-Bissau |
| 2020s | 1,020 constant 2022 US$ | 1,045 constant 2022 US$ | 25.4 constant 2022 US$ | Guinea-Bissau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Burundi or Guinea-Bissau?
- Guinea-Bissau, at 1,120 constant 2022 US$ against 1,051 constant 2022 US$ in Burundi as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Burundi and Guinea-Bissau?
- 69 constant 2022 US$, with Guinea-Bissau ahead.
- How many years of comparable data are there for Burundi and Guinea-Bissau?
- 8 years are reported by both, from 2017 to 2024.
- How do Burundi and Guinea-Bissau rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Burundi ranks 45th and Guinea-Bissau ranks 43rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.